---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-004957"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2025-02-18T23:59:59+00:00"
generated_at: "2026-05-26T14:14:11.856155+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GNI Group FY2024 revenue down 9.2%, operating profit plunges 89.3%; Gyre pipeline catalysts set for 2025

## Summary
- Revenue ¥23,611M (-9.2% YoY); operating profit ¥1,402M (-89.3%); pre-tax profit ¥238M (-98.1%).
- Net loss attributable to owners of parent ¥977M (vs. ¥8,094M profit in FY2023); basic EPS ¥19.55 (vs. ¥169.50).
- Operating cash flow negative ¥3,164M; investing cash outflow ¥10,361M; cash position ¥10,115M.
- Gyre Pharms: Hydronidone Phase 3 topline data expected Q1 2025; F573 Ph2 completion, F230 Ph1 start planned.
- F528 IND submission targeted for Dec 2025; GNI Group forecasts FY2025 revenue ¥28,733M (+21.7% YoY).

## SEC filing metadata
- accession: 0001140361-25-004957
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2025-02-18T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036125004957/0001140361-25-004957-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036125004957/ny20043721x1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-004957
- JSON: https://secwatch.observer/filing/0001140361-25-004957.json
- Plain text: https://secwatch.observer/filing/0001140361-25-004957.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.